1. Scrip
  2. >>Focus On Asia

Cynata Surges On Stem Cell Production Breakthrough

 
• By James Dunn

Shares in Melbourne-based stem cell manufacturer Cynata Therapeutics more than doubled on the Australian Securities Exchange (ASX) on Feb.19 after emerging from a 48-hour trading halt, as the company announced that its “world-first” production technology had passed a critical test in the U.S.

Cynata said it had found a way of mass-producing mesenchymal stem cells (MSCs), which are being closely investigated for their applicability in treatments for various diseases.

Demonstrating that it can make cells at an industrial scale under Good Manufacturing Practice (GMP) protocols positions the Australian venture...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?